Stay updated with breaking news from Dror Bashan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Protalix Biotherapeutics and Chiesi Global Rare Diseases Provide Regulatory Update on PRX-102 for the Treatment of Fabry Disease - read this article along with other careers information, tips and advice on BioSpace
/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and...
/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and...
Author Bio A Fool since 2019, Prosper's writing focuses primarily on the healthcare sector. Passionate about teaching and learning, he enjoys helping others make better decisions about their finances -- and enjoys it just as much when they return the favor. In his free time, you'll find him curling up with a good book or doing math. What happened? Shares of Protalix BioTherapeutics (NYSEMKT:PLX) are falling off a cliff on Wednesday after the company announced a disappointing regulatory update regarding one of its pipeline candidates, pegunigalsidase alfa (PRX-102). Th...
Protalix BioTherapeutics Inc (NYSE: PLX) and Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici, have received a ...